Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo
- 15 April 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (8) , 2512-2518
Abstract
Purpose: To optimally integrate epidermal growth factor receptor (EGFR) inhibitors into the clinical treatment of head and neck cancer, two important questions must be answered: (a) does EGFR inhibition add to the effects of radiochemotherapy, and (b) if so, which method of inhibiting EGFR is superior (an EGFR antibody versus a small molecule tyrosine kinase inhibitor)? We designed an in vivo study to address these questions. Experimental Design: Nude mice with UMSCC-1 head and neck cancer xenografts received either single, double, or triple agent therapy with an EGFR inhibitor (either cetuximab or gefitinib), gemcitabine, and/or radiation for 3 weeks. Tumor volumes and animal weights were measured for up to 15 weeks. Immunoblotting and immunofluorescent staining were done on tumors treated with either cetuximab or gefitinib alone. Results: The addition of an EGFR inhibitor significantly delayed the tumor volume doubling time, from a median of 40 days with radiochemotherapy (gemcitabine and radiation) alone, to 106 days with cetuximab and 66 days with gefitinib (both P < 0.005). Cetuximab resulted in significantly less weight loss than gefitinib. Immunoblot analysis and immunofluorescent staining of tumors show that although levels of phosphorylated AKT and extracellular signal–regulated kinase were decreased similarly in response to cetuximab or gefitinib, cetuximab caused prolonged suppression of pEGFR, pSTAT3, and BclXL compared with gefitinib. Conclusions: EGFR inhibition, particularly with cetuximab, improves the effectiveness of radiochemotherapy in this model of head and neck cancer. The correlation of response with prolonged suppression of EGFR, STAT3, and BclXL offers the possibility that these may be candidate biomarkers for response.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicityOncogene, 2006
- Integration of EGFR inhibitors with radiochemotherapyNature Reviews Cancer, 2006
- Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck CarcinomaCancer Research, 2006
- Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitorsAnnals of Oncology, 2005
- Epidermal growth factor receptor inhibition strategies in oncologyEndocrine-Related Cancer, 2004
- In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma CellsClinical Cancer Research, 2004
- Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)Clinical Cancer Research, 2004
- Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancerInternational Journal of Cancer, 2004
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancerSeminars in Oncology, 2002
- Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.Journal of Clinical Investigation, 1998